Acumen Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Acumen Pharmaceuticals, Inc. (ABOS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 20.22 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 19.37M shares, a 21.92% increase year-over-year.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 15.89M shares, a 20.73% increase year-over-year.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 13.16M shares, a 73.88% increase year-over-year.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.57M shares, a 53.75% increase year-over-year.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 16.21M shares, a 18.03% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 13.73M shares, a 43.44% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.57M shares, a 70.59% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.61M shares, a 46.28% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 20.22M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 19.37M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 16.21M shares 10-K · filed 2026-03-26 | |||
| 2025-09-30 | 16.15M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 16.18M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 15.89M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 13.73M shares 10-K · filed 2026-03-26 | |||
| 2024-09-30 | 13.50M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 13.34M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 13.16M shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 9.57M shares 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 7.73M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 7.72M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 7.57M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 5.61M shares 10-K · filed 2024-03-26 | |||
| 2022-09-30 | 5.66M shares 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 5.23M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 4.92M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 3.84M shares 10-K · filed 2022-03-28 | |||
| 2021-09-30 | 3.66M shares 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 32.15M shares 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | 24.19M shares 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 21.71M shares 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 9.85M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |